Gross Profit Comparison: Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Limited Trends

Bristol-Myers Squibb's profits soar, Teva's decline over a decade.

__timestampBristol-Myers Squibb CompanyTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20141194700000011056000000
Thursday, January 1, 20151265100000011356000000
Friday, January 1, 20161448100000011859000000
Sunday, January 1, 20171471000000010825000000
Monday, January 1, 2018160140000008296000000
Tuesday, January 1, 2019180670000007536000000
Wednesday, January 1, 2020307450000007725000000
Friday, January 1, 2021364450000007594000000
Saturday, January 1, 2022360220000006973000000
Sunday, January 1, 2023343130000007646000000
Monday, January 1, 2024363510000008064000000
Loading chart...

In pursuit of knowledge

A Tale of Two Giants: Bristol-Myers Squibb vs. Teva Pharmaceutical

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their market position and potential for innovation. Over the past decade, Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Limited have showcased contrasting trends in their gross profits. From 2014 to 2023, Bristol-Myers Squibb's gross profit surged by nearly 187%, peaking in 2021, while Teva's profits declined by approximately 30% over the same period. This divergence highlights Bristol-Myers Squibb's strategic growth and market adaptability, especially evident in the significant leap in 2020, whereas Teva faced challenges that impacted its financial trajectory. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the competitive dynamics and strategic maneuvers of these industry titans.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025